Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Schering supports China haemophilia centres

This article was originally published in Scrip

Executive Summary

Bayer Scheringhas pledged a total of €1.5 million over the next five years to fund the development of haemophilia treatment centres in China. The firm has linked with the Chinese Society of Hematology to provide equipment, supplies and educational materials to, and support patient and nursing programmes at, the six existing centres in the country, where an estimated 70,000 to 100,000 people suffer from the disorder. The aim is to develop the network to provide a full range of services in support of improved diagnosis and treatment. Bayer Schering markets Kogenate, currently the only recombinant Factor VIII product approved in China.

You may also be interested in...

Hit And Miss First Half For Takeda

While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.

Bumpy Japan Zolgensma Review Holds Lessons For Applicants

Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts